What are Regeneron Pharmaceuticals's profit margins?

Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.

Where do Regeneron Pharmaceuticals's ratios come from?

Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Regeneron Pharmaceuticals REGN Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Operating margin	24.3%-0.6pp	24.9%-0.9pp	25.9%-1.1pp	27%-0.2pp	27.2%-0.9pp
Net margin	29.6%-1.8pp	31.4%-0.7pp	32.1%+0.8pp	31.4%-0.6pp	31.9%+0.9pp
EBITDA margin	27.9%-0.8pp	28.7%-0.8pp	29.6%-1.0pp	30.6%-0.1pp	30.7%-0.8pp
Free cash flow margin	27.6%-0.9pp	28.4%-1.2pp	29.6%+2.5pp	27.1%+5.1pp	22%-3.8pp
Returns
Return on equity	14.5%-0.3pp	14.9%-0.3pp	15.2%-0.1pp	15.3%-0.6pp	16%0.0pp
Return on assets	11.3%-0.2pp	11.5%-0.3pp	11.8%-0.2pp	12%-0.5pp	12.5%+0.1pp
Return on invested capital	10.3%+0.2pp	10.1%-0.6pp	10.7%-1.1pp	11.8%-0.5pp	12.3%-0.9pp
Efficiency
Asset turnover	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×0.0×
Liquidity
Current ratio	3.6×-0.6×	4.1×+0.1×	4.1×-0.5×	4.6×-0.3×	4.9×+0.2×
Quick ratio	3×-0.4×	3.4×+0.1×	3.3×-0.4×	3.7×-0.3×	4×+0.1×
Cash ratio	0.6×-0.1×	0.7×+0.1×	0.6×0.0×	0.5×-0.3×	0.9×+0.2×
Leverage
Debt-to-equity	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Debt-to-assets	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Net debt / EBITDA	-0.1×0.0×	-0×-0.1×	0×-0.1×	0.2×+0.2×	-0.1×-0.2×
Interest coverage	75.6×-6.1×	81.7×-5.9×	87.6×-17.3×	104.9×+24.8×	80.1×+7.9×
Per Share
Book value per share	$291.77+1.4%	$287.82-0.3%	$288.79+4.8%	$275.68+4.3%	$264.28+3.6%
Valuation
Market capitalization	$81.68B+0.7%	$81.12B+36.1%	$59.59B+5.7%	$56.39B-18.7%	$69.34B-11.4%
Enterprise value	$81.42B+0.6%	$80.97B+35.4%	$59.79B+4.7%	$57.08B-17.2%	$68.95B-12.4%
Price / earnings	18.5×+0.5×	18×+5.0×	13×+0.4×	12.6×-2.8×	15.4×-2.3×
Price / sales	5.5×-0.2×	5.7×+1.5×	4.2×+0.2×	4×-1.0×	4.9×-0.6×
Price / book	2.6×0.0×	2.6×+0.7×	1.9×0.0×	1.9×-0.5×	2.4×-0.3×
EV / EBITDA	19.5×-0.1×	19.6×+5.5×	14.2×+1.1×	13.1×-2.8×	15.9×-1.7×
EV / sales	5.5×-0.2×	5.6×+1.4×	4.2×+0.2×	4×-0.9×	4.9×-0.6×
Free cash flow yield	5%0.0pp	5%-2.1pp	7.1%+0.2pp	6.8%+2.4pp	4.5%-0.2pp
Earnings yield	5.4%-0.1pp	5.6%-2.1pp	7.7%-0.2pp	7.9%+1.4pp	6.5%+0.9pp
Dividend yield	0.5%0.0pp	0.5%0.0pp	0.5%+0.1pp	0.3%+0.2pp	0.1%—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Regeneron Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Regeneron Pharmaceuticals's profit margins?: Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.
Where do Regeneron Pharmaceuticals's ratios come from?: Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.